Naropin is owned by Fresenius Kabi Usa.
Naropin contains Ropivacaine Hydrochloride.
Naropin has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Naropin are:
Naropin was authorised for market use on 24 September, 1996.
Naropin is available in solution;injection dosage forms.
The generics of Naropin are possible to be released after 28 November, 2026.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8118802 | FRESENIUS KABI USA | Connector for packaging containing medical fluids and packaging for medical fluids |
May, 2023
(16 days ago) | |
US8162915 | FRESENIUS KABI USA | Connector for packings containing medical liquids, and corresponding packing for medical liquids |
May, 2024
(11 months from now) | |
US7828787 | FRESENIUS KABI USA | Connector for packaging containing medical fluids and packaging for medical fluids |
Oct, 2025
(2 years from now) | |
US7857802 | FRESENIUS KABI USA | Connector for medical liquid-containing packages and medical liquid-containing packages |
Nov, 2026
(3 years from now) |
Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 September, 1996
Treatment: NA
Dosage: SOLUTION;INJECTION
9
European Union
5
Germany
4
United States
3
Australia
3
Korea, Republic of
3
Canada
3
Denmark
3
Spain
3
Portugal
3
Poland
3
Japan
3
Norway
3
Hong Kong
3
Slovenia
3
Mexico
3
Brazil
3
China
3
South Africa
2
Austria
1
India
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic